FAIR and interactive data graphics from a scientific knowledge graph
Contents
Clinical data | |
---|---|
Trade names | Gonazon |
Other names | 6-[3-(2-Naphthalenyl)-D-alanine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide; 6-[3-(2-Naphthalenyl)-D-alanine]-10-deglycinamide-luteinizing hormone-releasing factor (pig) 2-(aminocarbonyl)hydrazide |
Routes of administration | Implant; Injection |
Drug class | GnRH agonist |
Identifiers | |
| |
CAS Number |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C65H82N18O13 |
Molar mass | 1323.484 g·mol−1 |
3D model (JSmol) | |
| |
|
Azagly-nafarelin, sold under the brand name Gonazon, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in veterinary medicine in Europe.[1][2] It is a GnRH analogue and a synthetic peptide, specifically a decapeptide.[1][2][3] The medication has been approved in Europe as a solid silicone-based matrix implant for use as a contraceptive in animals such as male dogs, cats, and others, but is no longer or was never commercially available.[1][2][4][5] The medication has also been used to treat benign prostatic hyperplasia in animals.[6][7] In addition to its use in mammals, azagly-nafarelin has been approved for use in aquaculture fish, specifically to control ovulation in salmonids, and was the first GnRH agonist to be available for use in fish.[2][8] It was introduced for use by 2005.[9]
See also
References
- ^ a b c Driancourt MA, Rodes L (29 June 2018). "Male Contraception in Animal Species". In Skinner MK (ed.). Encyclopedia of Reproduction. Elsevier Science. pp. 554–556. ISBN 978-0-12-815145-7.
- ^ a b c d Löscher W, Richter A, Potschka H (3 September 2014). Pharmakotherapie bei Haus- und Nutztieren: Begründet von W. Löscher, F.R. Ungemach und R. Kroker. Enke. pp. 435–. ISBN 978-3-8304-1251-9.
- ^ Bulldan A, Shihan M, Goericke-Pesch S, Scheiner-Bobis G (December 2016). "Signaling events associated with gonadotropin releasing hormone-agonist-induced hormonal castration and its reversal in canines". Molecular Reproduction and Development. 83 (12): 1092–1101. doi:10.1002/mrd.22751. PMID 27764533. S2CID 29559009.
- ^ Rhodes L (April 2017). "New approaches to non-surgical sterilization for dogs and cats: Opportunities and challenges". Reproduction in Domestic Animals = Zuchthygiene. 52 (Suppl 2): 327–331. doi:10.1111/rda.12862. PMID 27892642.
- ^ Norman ST, Collop TM (30 April 2014). "Male Animal Contraception". In Chenoweth PJ, Lorton S (eds.). Animal Andrology: Theories and Applications. CABI. pp. 489–. ISBN 978-1-78064-316-8.
- ^ Christensen BW (July 2018). "Canine Prostate Disease". Veterinary Clinics of North America: Small Animal Practice. 48 (4). Elsevier Health Sciences: 701–719. doi:10.1016/j.cvsm.2018.02.012. ISBN 978-0-323-61085-8. PMID 29933768. S2CID 49381344.
- ^ Dreier HK (6 December 2010). "Hormonbehandlung bei der Hüdin". Klinik der Reproduktionsmedizin des Hundes. Schlütersche Verlagsgesellschaft mbH & Company KG. pp. 286–. ISBN 978-3-8426-8038-8.
- ^ Mylonas CC, Zohar Y (20 August 2007). "Promoting oocyte maturation, ovulation, and spawning in farmed fish". In Babin PJ, Cerdà J, Lubzens E (eds.). The Fish Oocyte: From Basic Studies to Biotechnological Applications. Springer Science & Business Media. pp. 444–. ISBN 978-1-4020-6233-9.
- ^ Haffray P, Enright WJ, Driancourt MA, Mikolajczyk T, Rault P, Breton B (2005). "Optimization of breeding of salmonids: Gonazon, the first officially approved inducer of ovulation in the EU". World Aquaculture. Archived from the original on 2018-07-29. Retrieved 2018-07-29.